Ocugen, Inc.
NASDAQ:OCGN · NASDAQ Capital Market
+$0.03 today
Vol 26.19M · Avg 7.51M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:OCGN · Revenue to Net Income
Key Ratios
Analysis
$4.5M of revenue converted into -$71.7M of net income for the selected period. Gross margin is 100.0% and net margin is 1426.3%, showing how much revenue survives after costs and taxes. EPS is $-0.23, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.4M +8.8% | $4.1M -32.8% | $6.0M +142.6% | $2.5M | $0 | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $2.4M +21.4% | $2.0M +179.5% | $704.0K | $0 | $0 | $725.6M | $804.0M | $882.4M |
| Gross Profit | $2.0M -3.0% | $2.1M -60.9% | $5.3M +114.3% | $2.5M | $0 | $8.9B | $7.6B | $6.2B |
| Gross Margin | 45.9% -5.6pp | 51.5% -36.9pp | 88.3% -11.7pp | 100.0% | — | 9.8% | 28.9% | 38.3% |
| Research & Development | $39.8M +23.7% | $32.1M -18.8% | $39.6M -29.5% | $56.2M +60.0% | $35.1M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $27.6M +3.3% | $26.7M -16.6% | $32.0M -9.6% | $35.4M +54.5% | $22.9M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $64.9M +14.2% | $56.8M -19.8% | $70.9M -22.6% | $91.6M +57.8% | $58.0M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $2.4M +21.4% | $2.0M +179.5% | $704.0K +46.7% | $480.0K +109.6% | $229.0K | $374.2M | $1.2B | $631.8M |
| EBITDA | -$60.3M -15.7% | -$52.1M +16.5% | -$62.4M +27.7% | -$86.3M -48.6% | -$58.1M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -1365.7% -81.2pp | -1284.5% -251.1pp | -1033.4% +2436.2pp | -3469.6% | — | 5.6% | 46.3% | 42.0% |
| Operating Income | -$62.9M -14.9% | -$54.8M +16.4% | -$65.5M +26.4% | -$89.1M -53.5% | -$58.0M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -1425.7% -75.3pp | -1350.4% -264.7pp | -1085.7% +2494.4pp | -3580.0% | — | 16.6% | 24.1% | 22.0% |
| Interest Income | $922.0K -29.1% | $1.3M -48.0% | $2.5M +78.6% | $1.4M | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $5.2M | $0 | $0 | $0 -100.0% | $79.0K | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$4.9M -801.3% | $703.0K -71.3% | $2.5M +8.2% | $2.3M +682.8% | -$389.0K | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$67.8M -25.5% | -$54.1M +14.3% | -$63.1M +27.3% | -$86.8M -48.6% | -$58.4M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -1537.4% -204.4pp | -1333.0% -288.0pp | -1045.0% +2443.9pp | -3488.9% | — | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $0 | $0 | $0 | $0 +100.0% | -$52.0K | $1.3B | -$1.6B | $745.2M |
| Net Income | -$67.8M -25.5% | -$54.1M +14.3% | -$63.1M +27.3% | -$86.8M -48.7% | -$58.4M | $4.9B | $4.8B | $4.7B |
| Net Margin | -1537.4% -204.4pp | -1333.0% -288.0pp | -1045.0% +2443.9pp | -3488.9% | — | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$0 -15.0% | -$0 +23.1% | -$0 +35.0% | -$0 -33.3% | -$0 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$0 -15.0% | -$0 +23.1% | -$0 +35.0% | -$0 -33.3% | -$0 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $300.2M +10.8% | $271.0M +10.9% | $244.3M +13.9% | $214.6M +10.0% | $195.0M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $300.2M +10.8% | $271.0M +10.9% | $244.3M +13.9% | $214.6M +10.0% | $195.0M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Alumis Inc. Common Stock
NASDAQ:ALMS
$2.85B
RAPT Therapeutics, Inc.
RAPT
$959.26M
Lexicon Pharmaceuticals, Inc.
NASDAQ:LXRX
$890.61M
Omeros Corporation
NASDAQ:OMER
$739.68M
Neurogene Inc.
NASDAQ:NGNE
$494.68M
Lineage Cell Therapeutics, Inc.
AMEX:LCTX
$304.14M
Compass Therapeutics, Inc.
NASDAQ:CMPX
$281.41M
Neumora Therapeutics, Inc. Common Stock
NASDAQ:NMRA
$271.16M
Fulcrum Therapeutics, Inc.
NASDAQ:FULC
$191.05M
ADC Therapeutics S.A.
NYSE:ADCT
$138.64M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does OCGN generate?
Ocugen, Inc. (OCGN) reported $4.41M of revenue in fiscal 2025.
Is OCGN profitable?
Ocugen, Inc. (OCGN) reported -$67,846,000.00 of net income, with a net margin of -1537.4%.
Explore More
Continue the stock analysis
Jump to another research area for this company.